Work

Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies

Year: 2023

Type: review

Abstract: Humans possess abundant amounts of microorganisms, including bacteria, fungi, viruses, and archaea, in their gut. Patients with nonalcoholic fatty liver disease (NAFLD) exhibit alterations in their gut microbiome and an impaired gut barrier function. Preclinical studies emphasize the significance of the gut microbiome in the pathogenesis of NAFLD. In this overview, we explore how adjusting the gut microbiome could serve as an innovative therapeutic strategy for NAFLD. We provide a summary of current information on untargeted techniques such as probiotics and fecal microbiota transplantation, as well as targeted microbiome-focused therapies including engineered bacteria, prebiotics, postbiotics, and phages for the treatment of NAFLD.

Source: Gut Microbes

DOI: 10.1080/19490976.2023.2226922

Authors: Mijra Koning, Hilde Herrema, Max Nieuwdorp, Abraham S. Meijnikman

Institutions: Amsterdam UMC Location University of Amsterdam, Amsterdam University Medical Centers, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism

Language: English

Topic: Gut microbiota and health

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,060